SIRT7 and glioma: As SIRT7 is a validated downstream target of miR-148a-3p and promotes glioblastoma cell proliferation and survival, we next investigated whether its suppression could enhance the efficacy of TMZ, a standard chemotherapeutic agent used in glioma treatment.